Augmentation of omega-3 fatty acid with antidepressants for major depressive disorder: a double-blind, randomized controlled trial
- Conditions
- major depressive disorder
- Registration Number
- JPRN-UMIN000013525
- Lead Sponsor
- niversity of Occupational and Environmental Health
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Not provided
1.History of schizophrenia, schizoaffective disorder or bipolar disorder (DSM-IV) as judged by treating physician. 2.Current dementia, borderline personality disorder, eating disorder or substance dependence (DSM-IV) as judged by treating physician. 3.Imminent high risk of suicide as judged by treating physician. 4.Use of antipsychotic drugs and antidepressant drugs within 1 week of the visit 5.Physical diseases which may contraindicate treatment with escitalopram. 6.Currently pregnant or breast-feeding women 7.Regular consumption of polyunsaturated fatty acid supplements within the last 3 months 8.A habit of eating fish >= 4 times per week, to ensure comparability to patients studied in Western countries.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Hamilton Raing Scale for Depression[Time frame: 12 weeks]
- Secondary Outcome Measures
Name Time Method MADRS SDS BDI QIDS-J CGI-S RS-14 Serum BDNF, proBDNF, MMP-9, fatty acid level Plasma IL-6